NCT02874430 is a Phase 2 clinical trial of Metformin Hydrochloride in Breast Carcinoma, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.

What drugs are being tested in NCT02874430?

Interventions in NCT02874430: Metformin Hydrochloride, Doxycycline.

What condition does NCT02874430 study?

NCT02874430 studies Breast Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Uterine Corpus Cancer, Uterine Corpus Carcinosarcoma.

Is NCT02874430 still recruiting?

NCT02874430 is currently terminated. Last updated 31 March 2026.

Are results published for NCT02874430?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2026-03-31 · How we verify

NCT02874430

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase II Study of Metformin in Combination With Doxycycline in Patients With Localized Breast, and Uterine, and Cervical Cancer

Terminated Phase 2 Results posted Last updated 31 March 2026

What this trial tests

Phase 2 trial testing Metformin Hydrochloride in Breast Carcinoma in 29 participants. Terminated before completion.

Timeline

8 June 2016

Primary endpoint
11 December 2020

11 December 2020

Quick facts

Lead sponsor	Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	29
Start date	8 June 2016
Primary completion	11 December 2020
Estimated completion	11 December 2020
Sites	1 location across United States

Drugs / interventions tested

Metformin Hydrochloride — full drug profile →
Doxycycline (doxycycline) — full drug profile →

Conditions studied

Breast Carcinoma — all drugs for Breast Carcinoma →
Endometrial Clear Cell Adenocarcinoma — all drugs for Endometrial Clear Cell Adenocarcinoma →
Endometrial Serous Adenocarcinoma — all drugs for Endometrial Serous Adenocarcinoma →
Uterine Corpus Cancer — all drugs for Uterine Corpus Cancer →

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Who can join

18 and older, female only, with Breast Carcinoma or Endometrial Clear Cell Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Change in the Percentage of Stromal Cells Expressing Caveolin-1 (CAV1) at an Intensity of 1+ or Greater by Immunohistochemistry
Time frame: Pre-treatment (Baseline) and Post-treatment (week 6)
Caveolin-1 (CAV1) expression in stromal cells is assessed by immunohistochemistry using a standard intensity scale of 0 to 3+, where 0 indicates no staining and 1+, 2+, and 3+ indicate increasing levels of staining intensity. For this measure, stromal cells with CAV1 staining of 1+ or higher are considered positive. Results are reported as the percentage of positive stromal cells, ranging from 0%

Sponsor's own description

This phase II trial studies how well metformin hydrochloride works together with doxycycline in treating patients with localized breast or uterine cancer. Metformin hydrochloride may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Doxycycline may stop the growth of bacteria by keeping them from making proteins and minimized the toxic side effects of anti-cancer therapy. It is not yet known whether giving metformin hydrochloride together with doxycycline may be a better way in treating patients with localized breast or uterine cancer.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

The updated landscape of tumor microenvironment and drug repurposing.
Jin MZ, Jin WL. · · 2020 · cited 900× · PMID 32843638 · DOI 10.1038/s41392-020-00280-x
Reactive Oxygen Species in the Tumor Microenvironment: An Overview.
Weinberg F, Ramnath N, Nagrath D. · · 2019 · cited 301× · PMID 31426364 · DOI 10.3390/cancers11081191
Stromal Modulators of TGF-β in Cancer.
Costanza B, Umelo IA, Bellier J, Castronovo V, et al · · 2017 · cited 129× · PMID 28067804 · DOI 10.3390/jcm6010007
New drugs are not enough‑drug repositioning in oncology: An update.
Armando RG, Mengual Gómez DL, Gomez DE. · · 2020 · cited 72× · PMID 32124955 · DOI 10.3892/ijo.2020.4966
Metformin: The Answer to Cancer in a Flower? Current Knowledge and Future Prospects of Metformin as an Anti-Cancer Agent in Breast Cancer.
Samuel SM, Varghese E, Kubatka P, Triggle CR, et al · · 2019 · cited 58× · PMID 31835318 · DOI 10.3390/biom9120846
Metformin as a Therapeutic Target in Endometrial Cancers.
Lee TY, Martinez-Outschoorn UE, Schilder RJ, Kim CH, et al · · 2018 · cited 52× · PMID 30211120 · DOI 10.3389/fonc.2018.00341
Repurposing non-oncology small-molecule drugs to improve cancer therapy: Current situation and future directions.
Fu L, Jin W, Zhang J, Zhu L, et al · · 2022 · cited 47× · PMID 35256933 · DOI 10.1016/j.apsb.2021.09.006
Therapeutic Repurposing of Biguanides in Cancer.
Zhao H, Swanson KD, Zheng B. · · 2021 · cited 47× · PMID 33865798 · DOI 10.1016/j.trecan.2021.03.001

Verify or expand the search:

Other trials of Metformin Hydrochloride

Trials testing the same drug.

NCT07380841 — Metformin vs Inositol vs Diet vs Combination Therapy in PCOS · NA · completed
NCT06899061 — Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saru · Phase 1 · active not recruiting
NCT06920056 — A Study of BGM0504 in Overweight or Obese Participants · Phase 1 · completed
NCT06638671 — Short-Term Metformin Use in Young, Healthy Adults: Impacts on Exercise Capacity · Phase 4 · recruiting
NCT05828303 — A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastat · Phase 1 · withdrawn

Other recruiting trials for Breast Carcinoma

Currently open trials in the same condition.

NCT07067138 — A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS- · NA · recruiting
NCT07291414 — A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients · NA · recruiting
NCT07338721 — Does Ultrasound Guidance Axillary Incision Improve Sentinel Lymph Node Detection in Breast Cancer? · recruiting
NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
NCT06731894 — Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors · Phase 2 · recruiting

Other Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University trials

Trials by the same sponsor.

NCT06974981 — Leveraging Lung Cancer Screening to Optimize Screening Outcomes and COPD Management: COPD in LCS Registry · recruiting
NCT03796884 — Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer · Phase 2 · active not recruiting
NCT03712904 — Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma · Phase 2 · terminated
NCT03807492 — Evaluation and Management for Prostate Oncology, Wellness, and Risk (EMPOWeR) · completed
NCT03477864 — Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progres · Phase 1 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02874430 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Last refreshed: 31 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02874430.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing